selected scholarly activity
-
conferences
- LONG-TERM TOXICITY IN PATIENTS RECEIVING RADIOTHERAPY FOR ULTRACENTRAL STAGE I NON-SMALL CELL LUNG CANCER - A SECONDARY ANALYSIS OF THE LUSTRE RANDOMIZED TRIAL. Radiotherapy and Oncology. S59-S59. 2023
- The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017. International Journal of Radiation Oncology Biology Physics. e430-e430. 2021
- Cardiac Toxicity in Central Non-Small Cell Lung Tumors treated with Stereotactic Body Radiation Therapy (SBRT) – Is there a “No-Flutter Zone”?. International Journal of Radiation Oncology Biology Physics. e138-e138. 2020
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464). International Journal of Radiation Oncology Biology Physics. S104-S104. 2020
- The Genomic Landscape of Anal Cancer and Its Relationship to Clinical Outcomes: An Exploratory Analysis of NRG Oncology/RTOG 98-11. International Journal of Radiation Oncology Biology Physics. S104-S105. 2019
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. International Journal of Radiation Oncology Biology Physics. 554-562. 2017
- PHASE I STUDY OF NEO-ADJUVANT STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OPERABLE PATIENTS WITH BORDERLINE RESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) (LINNEARRE I STUDY: NCT02433574). Radiotherapy and Oncology. S58-S59. 2016
- The Significance of p16 and p53 Expression on Clinical Outcome in Patients with Anal Cancer Treated with Chemoradiation Therapy: An Analysis of RTOG 98-11. International Journal of Radiation Oncology Biology Physics. S32-S32. 2014
- Pulmonary Function Test and Its Predictive Factors in Patients With Lung Malignancies Treated With Stereotactic Radiation Therapy: A Retrospective Review From a Single Institution. International Journal of Radiation Oncology Biology Physics. S550-S550. 2013
- The Significance of Coexpression of Epidermal Growth Factor Receptor (EGFR) and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiation Therapy: An Analysis of RTOG 98-11. International Journal of Radiation Oncology Biology Physics. S145-S145. 2012
- A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2010
- Priority health needs for patients receiving concurrent chemotherapy and radiation for stage III non-small cell lung cancer and impact of the role of the advanced practice nurse (APN). Journal of Thoracic Oncology. S436-S437. 2009
- Results of a Prospective Study on Brachytherapy in Lung Cancer in Combination with other Modalities. International Journal of Radiation Oncology Biology Physics. S440-S441. 2008
- P-126 Activation of tyrosine kinase receptors and intracellular signal mediators in NSCLC tumors. Lung Cancer. S148-S148. 2005
- P-252 Interim report: A phase III randomized double blindchemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer. Lung Cancer. S181-S181. 2005
- RADIOTHERAPY OF HODGKINS-DISEASE FOR RELAPSE FOLLOWING PRIMARY-TREATMENT BY CHEMOTHERAPY. Clinical and Investigative Medicine. B113-B113. 1987
-
journal articles
- Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.. Radiation Oncology. 19:155. 2024
- Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.. JAMA Oncology. 10:1571-1575. 2024
- Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial.. Radiotherapy and Oncology. 202:110605. 2024
- EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.. Journal of Thoracic Oncology. 19:s566. 2024
- Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer – A Secondary Analysis of the LUSTRE Randomized Trial. International Journal of Radiation Oncology Biology Physics. 117:S171-S171. 2023
- 128 Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer - A Secondary Analysis of the Lustre Randomized Trial. Radiotherapy and Oncology. 186:S59-S59. 2023
- Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials. JAMA network open. 6:e238504-e238504. 2023
- The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada. Frontiers in Oncology. 13:1210945. 2023
- LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 114:1061-1062. 2022
- Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials. American Journal of Clinical Oncology. 45:534-536. 2022
- 88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S39-S39. 2022
- 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017. Radiotherapy and Oncology. 163:S44-S44. 2021
- Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 7:1333-1333. 2021
- Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS ONE. 16:e0260857-e0260857. 2021
- 194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?. Radiotherapy and Oncology. 150:S83-S83. 2020
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer. 18:250-254. 2017
- Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study.. Journal of Clinical Oncology. 35:588-588. 2017
- 159: Phase I Study of NEO-Adjuvant Stereotactic Body Radiotherapy (SBRT) in Operable Patients with Borderline Resectable Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (Linnearre I Study: NCT02433574). Radiotherapy and Oncology. 120:S58-S59. 2016
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17:142-149. 2016
- Early Occurrence of Angiosarcoma in a Woman With a BRCA2 Gene Variation of Unknown Significance Treated With Breast-Conserving Therapy for Bilateral Ductal Carcinoma: A Case Report. Clinical Breast Cancer. 15:536-538. 2015
- Predicting 2-Year Survival for Radiation Regimens in Advanced Non-small Cell Lung Cancer. Clinical Oncology. 25:697-705. 2013
- Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597. Journal of Clinical Oncology. 31:4179-4187. 2013
- Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.. Gastrointestinal Cancer Research. 4:45-52. 2011
- A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28:CRA7004-CRA7004. 2010
- A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28:CRA7004-CRA7004. 2010
- Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy. Journal of Thoracic Oncology. 3:716-722. 2008
- P1-185: Progress report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase iii randomized double blind chemoprevention trial of selenium supplementation in resected stage i non small cell lung cancer. Journal of Thoracic Oncology. 2:S811-S811. 2007
- Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia. Journal of Clinical Oncology. 25:1027-1032. 2007
- Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. Journal of Clinical Oncology. 24:3953-3958. 2006
- Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns. Current Oncology. 13:124-129. 2006
- Management of unresected stage III non-small cell lung cancer: a systematic review.. Journal of Thoracic Oncology. 1:377-393. 2006
- Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer. 50:355-374. 2005
- P-125 p-38 MAPK, Erk and Akt expression and activation in NSCLCtumors; Subcellular distribution and radiographic response to radiotherapy. Lung Cancer. 49:S147-S148. 2005
- A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04). Journal of Clinical Oncology. 23:4019-4019. 2005
- Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary?. Lung Cancer. 46:379-380. 2004
- Response to issues raised by Dr. Debevec ?Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary??. Lung Cancer. 46:381-381. 2004
- Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 44:1-11. 2004
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer. 43:223-240. 2004
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.. Journal of Clinical Oncology. 20:1167-1174. 2002
- One year follow-up reveals no difference in quality of life between high dose and conventional dose radiation: a quality of life assessment of RTOG 94-05. International Journal of Radiation Oncology Biology Physics. 51:97-97. 2001
- Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute. 93:605-618. 2001
- The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. Current Oncology. 8:50-59. 2001
- Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer. Current Oncology. 7:98-109. 2000
- The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. Current Oncology. 7:162-172. 2000
- Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. Cancer Prevention and Control. 1:249-259. 1997
- Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.. Cancer Prevention and Control. 1:18-27. 1997
- A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. British Journal of Cancer. 73:1588-1593. 1996
- EUTHANASIA AND ETHICAL FOUNDATIONS. Humane medicine. 9:319-320. 1993
- Neutron Radiography of Fast Transient Processes. Nuclear Technology. 31:250-256. 1976
-
preprints